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Abstract
Transforming growth factor-beta1 (TGF-β1) plays a crucial role in tumor pro-
gression. It can inhibit early cancer stages but promotes tumor growth and
development at the late stages of tumorigenesis. TGF-β1 has a potent immuno-
suppressive function within the tumor microenvironment that largely contrib-
utes to tumor cells' immune escape and reduction in cancer immunotherapy
responses. Likewise, myeloid-derived suppressor cells (MDSCs) have been pos-
tulated as leading tumor promoters and a hallmark of cancer immune evasion
mechanisms. This review attempts to analyze the prominent roles of both
TGF-β1 and MDSCs and their interplay in cancer immunity. Furthermore,
therapies against either TGF-β1 or MDSCs, and their potential synergistic com-
bination with immunotherapies are discussed. Simultaneous TGF-β1 and
MDSCs inhibition suggest a potential improvement in immunotherapy or sub-
verted tumor immune resistance.
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1 | INTRODUCTION
Tumor progression lies in cancer cells' capacity to generate
favorable tumor microenvironment (TME) conditions to
grow and proliferate, and finally, to metastasize different
organs in the human body. One of the main collaborators
in the success of cancer progression is transforming growth
factor-beta 1 (TGF-β1), a secreted pleiotropic cytokine
implicated in almost all aspects of cancer cell biology,
including cell proliferation, survival, migration, cell differ-
entiation, angiogenesis, and metastasis. TGF-β1, depending
on the cell context and cancer stage, can negatively or
positively affect tumor cell proliferation and apoptosis. In
the early stages of tumor progression, it often displays
tumor-suppressive functions, but at the late stages of tumor-
igenesis, cancer cells become refractory to TGF-β1, and cell
malignancy progresses alongside tumor growth and aggres-
sivity.1,2 Intratumoral TGF-β1 expression is elevated com-
pared to “normal” surrounding tissues, and elevated
cancer-associated TGF-β1 level is a useful tool as a poor
prognosis marker.
Furthermore, protumorigenic TGF-β1 functions also
consider the effects of all nontransformed cellular com-
ponents of TME.3-5 TGF-β1 regulates the tumor stroma
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inflammatory response by modulating the innate and
adaptive immune system's infiltration, generation, and
activity, forming a network of suppressive immune regu-
latory inputs.2,6 Consequently, to understand the tumor
promoter roles of TGF-β1, a full consideration of the
complex interplay of cancer cells and stromal cells is
required.
Among immune cells that may have an intimate
interplay with TGF-β1 to establish an immunosuppres-
sive TME, MDSCs have attracted great interest due to
their role in several pathological conditions, including
cancer.7,8 MDSCs are one of the main orchestrators of
cancer-related inflammation; they express different polar-
ized features that contribute to the inflammatory milieu
within TME and promote cancer cell outgrowth. Immu-
nosuppressive MDSCs function relies on the cancer sub-
version of the immune surveillance by repressing T-cell-
dependent immunity. Besides, MDSCs are recruited, acti-
vated, and expanded by cancer cell interactions and fac-
tors released by transformed cells, and they may closely
interact with other immune cells to establish a pathologi-
cal immune permissive TME that strongly supports
tumor progression.9-12 Beyond immunosuppressive func-
tions, TGF-β1 and MDSC may actively cooperate in many
other aspects of tumor progression, including extracellu-
lar matrix (ECM) reorganization, induction of cancer-
associated epithelial-to-mesenchymal transition (EMT),
and premetastatic niche formation.13,14 Therefore, inter-
fering with their cancer-associated functions is highly
needed. Many efforts and therapeutic strategies aim to
target TGF-β1 or MDSCs to recover or potentiate the
immune system's antitumor function. In this review, we
analyze the complex roles of TGF-β1 and MDSCs in can-
cer, and we also aim to convey insight into the main
aspects of the interplay of TGF-β1 and MDSCs in tumor
progression, focusing primarily on their mutual functions
in the regulation of TME-associated immune system.
Moreover, we address the current outcomes of targeting
TGF-β1 and MDSCs, which may open new ways of com-
bining immunotherapy to improve the success of new
and current oncotherapies to the benefit of cancer
patients' quality of life.
2 | TRANSFORMING GROWTH
FACTOR-Β1 SIGNALING
TGF-β1 is a secreted cytokine involved in a plethora of
distinct biological processes in tumor progression, includ-
ing cell growth and proliferation, differentiation and
development, apoptosis, angiogenesis, and immune
response suppression, and metastasis.2,4,6 Three TGF-β
types have been described so far in mammalians TGF-β1,
-β2, and -β3 with a high level of sequence homology but
with different expression modes and different functions.15
TGF-β1, also named TGF-β, is the one that has crucial
roles in tumor progression and development of a pro-
tumorigenic microenvironment.4,6 Although lacking the
classic TATA boxes, the TGF-β1 gene possesses multiple
regulatory cis-elements susceptible to activation by sev-
eral immediate early genes and oncogenes or inhibition
by tumor suppressors.16 TGF-β1 is synthesized as a
75 kDa precursor, that is, cleavage by furin-type con-
vertase to form a small latent complex (SLC) that con-
tains the latency-associated peptide (LAP) and TGF-
β1.17,18 SLC may bind to the latent TGF-β1 binding pro-
tein, giving rise to a large latent complex that, after secre-
tion, remains covalently associated with ECM for further
activation.19 The TGF-β1 complex may bind to the cell
surface membranes by crosslinking to leucine-rich
repeat-containing protein 32/33, transmembrane proteins
primarily expressed in immune cells. These proteins inter-
act and present pro-TGF-β1 to the cell surface of target
cells.20 Mechanisms of latent-TGF-β1 activation involve
proteolytic cleavage by plasmin and metalloproteinases,
oxidative stress, an acidic microenvironment, and integrin
interactions, among others.17,21
Following activation and release of mature TGF-β1,
its direct association with receptors on the plasma mem-
brane triggers a cascade of signal transduction pathways
responsible for its biological actions in target cells.18
TGF-β1 initiates its function by forming hexameric sig-
naling complexes with type I (TβR1) and type II (TβR2)
receptor kinases leading to the activation of canonical
and noncanonical pathways.22,23 In the canonical path-
way, the activated receptor complexes recruits and phos-
phorylate the cytoplasmic mediators Smad2 and
Smad3.24 Phosphorylated Smad2,3 are then released from
the plasma membrane's inner face, enabling their inter-
action with the common Smad4. The heteromeric effec-
tor complex is translocated to the nucleus to regulate the
specific target gene expression.22,25 Meanwhile, the TGF-
β1-Smad pathway also has a negative feedback mecha-
nism mediated by the inhibitory Smad7 that competi-
tively binds to TβR1 and blocks the Smad intracellular
signal transduction.26,27 Moreover, betaglycan, also
named TβR3, binds TGF-β1 with high affinity and pro-
motes TGF-β1 signaling by forming complexes with cell
surface receptor kinases.18,28
Noncanonical TGF-β1 pathways, also known as non-
Smad signaling, encompass the activation and crosstalk
with mitogen-activated protein kinases (MAPK), ERK1,2,
JNK, and p38; PI3K (phosphoinositide 3-kinase)/AKT1,2
and mTOR; NF-κB (nuclear factor κB), cyclooxygenase-2
and prostaglandins; the small GTPase proteins Ras, Rho
family of GTPases, among others.29,30
2 MOJSILOVIC ET AL.
Nonetheless, these non-Smad pathways do not neces-
sarily indicate TGF-β1 signaling since they can also be
activated by receptor tyrosine kinases.4 This plethora of
TGF-β1 signaling may explain this cytokine's capacity to
regulate various biological, cellular, and molecular
functions.
3 | TRANSFORMING GROWTH
FACTOR-Β1 IN CANCER
TGF-β1 can act as a tumor suppressor in the early stages
of tumorigenesis, mainly by inducing apoptosis in prema-
lignant cells and by inhibition of carcinoma cell prolifera-
tion, while at late stages of tumor progression, cancer cells
are under selective pressure, and TGF-β1 may become to
acts as a tumorigenic promoter.2,31 The critical roles of
TGF-β1 as a tumor promoter include pro-metastatic cancer
and stromal cell responses, EMT induction, and the devel-
opment of immune-suppressive TME.2,4,6,32
Part of the molecular armament for tumor suppressor
TGF-β1 activity is the capacity to potently inhibit epithelial
cell proliferation due to its ability to regulate cyclin-
dependent kinase (CDK) inhibitors. This cytokine induces
p15Ink4b and p21Cip1 expression to inhibit cyclinD-CDK4/6
and cyclinE/A-CDK2 complexes p16ink4a and p19ARF
expression that results in retaining the tumor-suppressor
retinoblastoma (Rb) protein in a hyperphosphorylated
state. Then, Rb forms complexes with the transcription
factors of the E2F family that contribute to cell arrest.33-36
Furthermore, TGF-β1 also inhibits cell cycle progression
by repressing the expression of the proliferation-inducing
transcription factor c-Myc and the inhibitors of DNA bind-
ing and cell differentiation (Id-1,-2, and -3) proteins.37-39
Besides, TGF-β1 may induce the process of apoptosis, in
part by upregulating the expression of the death-associated
protein kinase (DAP-kinase),40 through the interaction of
the adaptor protein DAXX with TβR2 to mediate JNK-
induced apoptosis,41 or by inducing ARTS (apoptotic
response to TGF-β signals) translocation from the mito-
chondria to the nucleus to inhibit X-linked inhibitor of
apoptosis protein functions.42
However, in the late stages of tumor progression, can-
cer cells become refractory to proliferation inhibition by
TGF-β1. Part of this lies in the fact that members of TGF-
β1 signaling are genetically inactivated, providing the
growth of cancer cells advantageous.4,36,38 Transformed
cells may suffer TGF-β1 receptor downregulation due to
deletions, gene mutation, or epigenetic silencing,43 which
causes compensatory TGF-β1 ligand overexpression and
increased aggressiveness of tumor cells.36 Moreover,
TβR2 is subjected to epigenetic silencing by histone and
DNA methylation.4 In this sense, treatment with a DNA
methyltransferase inhibitor 5-Aza-20-deoxycytidine
restores TβR2 expression and promotes cell cycle arrest
in esophageal squamous cell carcinoma.44 Besides, the
loss or reduced expression of TβR3 in several human can-
cers may exacerbate cancer cells' unresponsiveness to
inhibition by TGF-β1.45
Besides, homozygous deletion of SMAD4 gene and loss
of Smad4 protein expression occurs in human pancreatic
cancer, sporadic gastroenterological tumors, human skin
squamous cell carcinomas, human cervical cancer, head
and neck squamous cell carcinoma (SCC), and colorectal
cancer.46 Other germline mutations in SMAD4 have also
been described in the autosomal dominant familial juvenile
polyposis syndrome.47 Thus, these data support the idea
that Smad4 may act as a tumor suppressor protein. Mean-
while, inactivating mutations in SMAD2 have been found
in various cancers, including colorectal, lung, cervical, and
hepatocellular carcinomas,48 while low SMAD2 mRNA
expression correlates with better survival in oral SCC.49
Moreover, a hyperactive TGF-β-TβRs-Smad2 signaling axis
seems to be needed to maintain an epigenetic silencing crit-
ical for breast cancer progression.50 So far, no relevant
mutations linked to cancer have been discovered for inhibi-
tory SMAD6 and SMAD7 genes, but increased expression of
Smad6 in cancer attenuates Smad signaling and correlates
with better survival of oral squamous cell carcinoma
patients. At the same time, Smad7 is related to reduced
TGF-β1 signaling in hepatocellular carcinoma.49,51
Besides, the importance of TGF-β1 signaling in
tumorigenesis also lies in its capacity to regulate several
events that directly or indirectly stimulate cell malig-
nancy and metastasis. Protumorigenic TGF-β1 roles
include cancer cell migration, ECM reorganization and
degradation, EMT, tumor angiogenesis, and control of
immune surveillance that together make tumors more
aggressive and prone cancer cells to achieve a metastatic
phenotype.4,32,38,52 Interestingly, TGF-β1 expression level
correlates with the severity of the cancer disease, and it
may be a useful tool for diagnosis, prognosis, or a predic-
tive cancer marker. In human cancers, such as myeloma,
renal, prostate, breast, or pancreatic cancer, increased
TGF-β1 plasma level is associated with advanced cancer
stages, metastasis, and poor clinical outcome.53,54 More-
over, elevated serum levels of TGF-β1 are observed in
patients with myeloma, non-Hodgkin lymphoma, and
markedly elevated in high-grade lymphomas and cutane-
ous T cell lymphomas T-regulatory phenotype, and
splenic marginal zone lymphomas presented as myelofi-
brosis.55 and references therein Moreover, TGF-β1 can be pro-
duced by immune infiltrating myeloid cells or local
stromal cells, contributing to cancer progression and met-
astatic potential through autocrine and paracrine
effects.2,4
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FACTOR-Β1 AND IMMUNE SYSTEM
The TME comprises a diversity of innate and adaptive
immune cell types critical for fighting cancer, but the com-
plexity of cancer cell interaction with the immune system
elicits an immunosuppressive function that contributes to
cancer progression. TGF-β1 is one of the most critical
players in displaying an immune-tolerant microenviron-
ment that allows cancer cells to escape from immune sur-
veillance.2,4,56,57 Although cancer cells may express tumor-
specific antigens that the immune system can recognize,
they often evade immunosurveillance, making tumor
immunotherapy unsuccessful. TGF-β1 may directly or
indirectly regulate the immune response to cancer.58 TGF-
β1 downregulates MHC Class I molecules in cancer cells,
promoting escape from immunosurveillance,56 while regu-
lates the systemic immune response and immune response
within TME.55-57
Besides cancer cells, different immune cell types, such
as macrophages, dendritic cells (DC), and T-cells,
strongly contribute to increased levels of tumor
microenvironment-associated TGF-β1.59 Although TGF-
β1 is the most expressed TGF-β isoform in the immune
system, its importance as a master regulator of mamma-
lian immune system function and homeostasis was ini-
tially highlighted by the observation that Tgf-β1
−/− mice
exhibit a lethal multiorgan inflammation due to a mas-
sive T-cell response dysregulation.60,61 Consequently, the
smad3 knockout mouse shows severe responsiveness and
chemotaxis defects in neutrophils, T-cells, and B-cells,
and these animals died of suffering from multiorgan
inflammatory injuries.62 Besides, smad3−/− T-cells were
unable to differentiate into T regulatory (Tregs) cells;
instead, these T-cells move toward Th17 phenotype in
response to TGF-β1 and interleukin (IL)-6.63 In turn,
transgenic mice harboring T-cells with truncated TβR2
exhibit severe autoimmune reactions due to massive
autoantibody production and multiorgan inflamma-
tion.60,64 TGF-β1 profoundly regulates T-cells, natural
killer (NK) cells, neutrophils, dendritic cells (discussed
later in the text), and monocyte/macrophage functions.
TGF-β1 promotes monocyte recruitment within TME and
contributes to monocyte to macrophage differentiation.65
Moreover, TGF-β1 suppresses mouse macrophages'
expression of tumor necrosis factor (TNF)-α, macrophage
inflammatory protein (MIP)-1α and MIP-2, contributing
in that way to the resolution phase of inflammation.66
Intratumorally, TGF-β1 induces macrophage polarization
toward tumor-associated M2-like phenotype.67,68 In neu-
trophils, TGF-β1 may inhibit these cells' ability to elimi-
nate cancer cells expressing Fas-ligands and, similarly to
macrophages, promotes tumor-associated N2-like
phenotype of tumor-infiltrating neutrophils.69 Thus,
TGF-β1 modulates the initiation and stimulation of
innate and adaptive immunity, thereby dampening anti-
cancer immune function and immunotherapy.4,70,71
5 | MYELOID-DERIVED
SUPPRESSOR CELLS
MDSCs are a heterogeneous population consisting of mye-
loid progenitor cells and immature myeloid cells, charac-
terized by the lack of surface markers associated with fully
differentiated myeloid cells and their morphological
resemblance to granulocytic and monocytic cells.14,72 Stud-
ies from 1960-80s have established that cancer develop-
ment is commonly associated with pathological expansion
and activation of groups of myeloid cells.14,73-76 Myeloid
cells exhibit an immature phenotype initially described in
mouse models bearing human tumors and later discovered
in patients with head and neck squamous cell cancer
(HNSC).77-79 In 2007, the term myeloid-derived suppressor
cells was coined,80 and they are recognized as a hallmark
of cancer progression and as a central mechanism of
immune surveillance evasion by cancer cells due to their
immunosuppressive potency.81,82
Myelopoiesis is under tight control in a steady-state,
and MDSCs are mainly produced in the bone marrow as
nonpolarized cells that maintain a basal suppressive
milieu. Moreover, MDSCs can migrate to peripheral
organs and differentiate into mature neutrophils, macro-
phages, or DC to support normal immune functions.80
Under pathological stimuli, including infection, tissue
damage, and cancer, among others, bone marrow emer-
gency myelopoiesis is induced in response to inflammatory
factors such as colony-stimulating factors, chemokines,
and some cytokines. These factors can stimulate the
expansion of MDSCs with high immunosuppressive capac-
ity, representing a protective cellular mechanism of
preventing excessive tissue damage due to unresolved
immune responses.83-85 Furthermore, chronic inflamma-
tion stimulates extramedullary myelopoiesis, generating
MDSCs in the spleen and peripheral lymphoid organs and
MDSCs recruitment into inflamed tissues contributing to
the resolution of inflammatory responses.84
In general, MDSCs represent a small group of mye-
loid progenitors as well as immature mononuclear cells.
They can be classified into two main groups: polymor-
phonuclear MDSCs (PMN-MDSCs, previously named as
granulocytic MDSCs) and defined as CD11b+, CD33+,
CD15+ or CD66b+, CD14−; monocytic MDSCs (M-
MDSCs), which share a morphological and phenotypical
characteristic with monocytes, and defined as CD11b+,
CD14+, CD15−, HLA-DR−/low, which distinguish them
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from HLA-DRhi monocytes. Another MDSCs population
has been recently described in human peripheral blood
mononuclear cells as HLA-DR−, CD33+ CD14− CD15−,
which compromises immature progenitors and are
referred to as “early-stage MDSCs” (eMDSCs).86,87 On the
other hand, their mouse MDSC counterpart
immunophenotypes include the expression of Gr-1 (that
share common epitopes with Ly6C and Ly6G) and
CD11b. Two categories can be defined, PMN-MDSC as
CD11b+ Ly6G+ Ly6Clo, and M-MDSC as CD11b+
Ly6G−, Ly6Chi.1,87
Besides the phenotypic delineations of MDSCs, effectors
underlying their development and function have been stud-
ied. MDSCs generation, expansion, accumulation, and func-
tional activities are orchestrated by different cytokines,
growth factors, signal transduction pathways, transcription
factors, and microRNAs (miRs) (reviewed in 88 and refer-
ences therein) (Figure 1), reviewed in 88 and references
therein which together shape MDSCs to protumorigenic
phenotype.7 For instance, IL-6 and granulocyte monocyte
colony-stimulating factor (GM-CSF) play essential roles in
MDSCs generation and immunosuppressive function.
When combined, they promote MDSCs with inhibitory
function on CD8+ T cells. Moreover, the IL-6/GM-CSF
combination, mediated by STAT3, increases CCR5 expres-
sion that enhances MDSCs migration into the melanoma
microenvironment.89 Consistently, IL-6 and GM-CSF com-
binations generate suppressive CD33+ MDSCs from human
peripheral blood mononuclear cells (PBMC).90 Moreover,
granulocyte colony-stimulating factor (G-CSF) and GM-
CSF, in a STAT3- or STAT5-dependent manner, promote
MDSCs expansion by downregulating the negative regula-
tor interferon regulatory factor (IRF)-8 expression. Consis-
tently, IRF-8-deficient mice generate tumor-like MDSCs,
while IRF-8 overexpression reduced MDSCs accumula-
tion.91 Other cytokines, such as interferon (IFN)-γ, IL-1β,
tumor necrosis factor (TNF)-α, and vascular endothelial
growth factor, also promote MDSCs expansion and suppres-
sive capabilities.reviewed in 92,93, and references therein STATs fac-
tors actively contribute to the MDSCs generation and
immunosuppression activity. Actually, STAT3 increased
reactive oxygen species (ROS) levels by upregulation of p47
FIGURE 1 Overview of the main effectors in MDSCs expansion and development. Cytokines and other bioactive factors, transcription
factors, hypoxia, and microRNAs mediate the production of MDSCs. Blue letters and arrows mean positive regulation; red letters and arrows
mean negative MDSCs expansion and development regulation. For more details, see the text. C/EBPβ, CCAAT-enhancer-binding protein β;
G-CSF, Granulocyte colony-stimulating factor; GM-CSF, Granulocyte-macrophage colony-stimulating factor; HMGB1, High mobility group
protein B1; IL-1β/6, Interleukin -1β/6; IRF8, Interferon Regulatory Factor 8; MDSCs, Myeloid-derived suppressor cell; S100A8/9, S100
Calcium Binding Protein A8; STAT3/5/6, Signal transducer and activator of transcription 3/5/6; miR, microRNAs; NF-κB, nuclear factor-
kappa B
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and gp91 subunits of NADPH oxidase enzyme complex
(NOX),94 and STAT3 increased inhibition dramatically
diminishes human malignant melanoma-derived M-MDSCs
immunosuppressive activity.95 Conversely, STAT6-deficient
mice with primary tumors have elevated levels of MDSCs
with elevated Arg1 and ROS expression that consequently
inhibit T cell activation.96
Besides, NF-κB signaling contributes to the increase of
MDSCs accumulation and function in response to various
proinflammatory factors, including S100A8/A9, high
mobility group box protein 1 (HMGB1), and IL-1β.97
Besides, the specific hematopoietic lineage deletion of the
CCAAT/enhancer-binding protein beta (C/EBPβ) tran-
scription factor in mice impairs MDSCs expansion and
immunosuppressive activity in mice bearing fibrosarcoma
tumors. In contrast, adoptive transfer of tumor antigen-
specific CD8+ T cells eradicates tumors in C/EBPβ defi-
cient mice, thus suggesting C/EBPβ as a critical regulator
of the immunosuppressive TME.7,98
Another study demonstrated that mouse myeloid-
specific Src homology-2 domain-containing inositol
59-phosphatase-1 (SHIP-1) ablation leads to MDSC expan-
sion. SHIP1 reduction correlates to increased levels of G-
CSF that in part enhances MDSCs frequency.99 Moreover,
SHIP-1 expression in splenocytes is downregulated in vivo
and correlates with MDSCs expansion and function, con-
tributing to pancreatic tumor progression.100
Hypoxia/hypoxia-inducible factor (HIF)-1α axis within
the tumor microenvironment also promotes the differenti-
ation and function of PMN-MDSC in a murine lympho-
blast ascites model in C57BL/6 strain. Interestingly, when
MDSCs isolated from the spleens of tumor-bearing mice
were transferred i.v. or injected directly into ascites, they
redirected their differentiation toward tumor-associated
macrophages at the hypoxic tumor sites. Furthermore,
MDSCs cultured under hypoxia condition acquired a mac-
rophage phenotype (Gr-1−, CD11b+, F4/80+).101
MiRs are noncoding single-stranded RNAs approxi-
mately 22 nucleotides long that regulate gene expression.
MiRs may enhance or inhibit MDSCs accumulation and
their suppressive potency. For instance, in the B16-F10
melanoma and 4T1 mammary carcinoma mouse cancer
model, the tumor-infiltrating MDSCs expressed an
increased level of miR-210 with enhanced immunosup-
pressive capacity. Furthermore, HIF-1α increases tumor-
associated MDSCs expression of miR-210 by binding
transcriptionally active hypoxia-response elements at its
proximal promoter, and, under normoxic conditions,
miR-210 overexpression is enough to enhance MDSCs-
induced T-cell suppression.102 Besides, miR-21 and miR-
155 are induced by GM-CSF and IL-6 in bone marrow-
derived MDSCs and further expand both PMN-MDSCs
M-MDSCs, mainly by STAT3 activation pathway.103,104
Conversely, miRs 17-5 and 20a silence STAT3 activity
and expression, which results in negative regulation of
MDSCs suppressive function.105 Recently, Han et al106
demonstrated that miR-449c expression is upregulated in
myeloid progenitor cells due to C-X-C motif chemokine
receptor (CXCR)-2 activation, and miR-449c increases M-
MDSCs generation due to downregulation of STAT6
mRNA and protein expression. Nonetheless, the number
of miRs contributing to MDSCs function is increasing
and has been reviewed in detail elsewhere.107
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SUPPRESSOR CELLS IN CANCER
PROGRESSION
Due to its multicellular complexity, cancer is now consid-
ered an ecological disease, with an active interaction
between transformed cells, fibroblasts, mesenchymal
cells, and tumor-infiltrating immune cells, which
together profoundly modulate tumor growth, progres-
sion, and metastasis.108,109 Myeloid cells comprise the
major nontransformed cellular component in the tumor
microenvironment; these cells include DCs, granulocytes,
macrophages, and MDSCs.9,110
MDSCs can support cancer progression by enhancing
tumor growth, neoangiogenesis, and metastasis, and they
are abundant within TME and spleen, and peripheral
blood.111,112 In general, it is accepted that MDSCs support
tumor growth and metastasis due to their capacity to pro-
tect cancer cells from immune surveillance, facilitate
TME reorganization, contribute to pre-metastatic niche
formation, and promote cancer-EMT.13
MDSCs may promote primary tumor progression by both
immunological (discussed later) and nonimmunological
mechanisms. To support tumor progression, MDSCs can
induce cancer cells to lose the epithelial phenotype and
acquire a more aggressive mesenchymal phenotype, a cellu-
lar program known as cancer-associated EMT, which posi-
tively contributes to enhanced tumor malignancy and
metastasis.113 Several MDSCs-derived soluble factors are
involved in EMT induction, such as TGF-β1, hepatocyte
growth factor, epidermal growth factor, and IL-6, among
others.114 In vivo, PMN-MDSCs depletion diminishes cancer
cells displaying EMT phenotype frequency in primary
tumors.104 Furthermore, pancreatic tumor-derived M-MDSCs
trigger aldehyde dehydrogenase 1 (ALDH1)-expressing can-
cer stem cell expansion with enhanced metastatic
characteristics,115 cell-cell contact between cancer cells and
MDSCs produce a stem-like phenotype of these tumor cells.
MDSCs-cancer cell interactions induce miR-101 upregulation
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in neoplastic cells that inhibit the co-repressor gene C-
terminal binding protein-2, involved in regulating stem cell
gene expression.116 Consistently, MDSCs enhance the
stemness biomarkers NANOG and c-MYC expression in epi-
thelial ovarian cancer (EOC) cells in coculture conditions.
MDSCs provoke increased colony-stimulating factor
2 (CSF2) production by EOC cells that in turn activate
STAT3 signaling in an autocrine way to further stimulate
cancer cells' stemness.117
Besides, PMN-MDSCs-derived exosomes containing
miR-143-3p promote lung cancer progression by acceler-
ating cell proliferation. miR-143-3p directly targets the
integral membrane protein 2B that has been shown to
inhibit cancer cell proliferation and induce apoptosis.118
Meanwhile, PMN-MDSCs in papillary thyroid carcinoma
(PTC) enhance invasive cancer cell capabilities both
in vitro and in vivo. PMN-MDSCs decrease miR-486-3p
expression, allowing NF-κB2 activation, contributing to
accelerated invasion of PTC cells.119
Interestingly, MDSCs support cancer cell motility and
tumor invasion by ECM remodeling, epithelial basement
membrane reorganization, and modified matrix stiff-
ness.120 Mainly, ECM structure is reorganized by
degrading proteins released by cancer cells and MDSCs,
including enzymes of the matrix metalloproteinases
(MMPs) family.121 Notably, MDSCs produce MMP2,
MMP8, MMP9, MMP13, and MMP14 that facilitate
tumor cell migration through ECM.122 Moreover, ECM
degradation increases matrix-bounding factor bioavail-
ability, such as TGF-β1 and VEGF, that propitiate tumor
neoangiogenesis and increase cancer cell invasiveness
and metastasis.13,112 Intriguingly, mouse MDSCs contrib-
ute to tumor endothelium development since they can
transdifferentiate toward VEGFR2+ endothelial cells.123
The formation of new vessels is vital for cancer cell dis-
semination; MDSCs may induce dysfunctional tumor vas-
culature formation permissive to tumor cell
intravasation.112 In both melanoma and liver cancer,
PMN-MDSCs increase transendothelial migration of
transformed cells by integrin (MAC-1)-ICAM-1 interac-
tion, while neutrophils and inflammatory monocytes,
like cancer MDSCs, facilitate extravasation when associ-
ated with cancer cells.112,124,125
Increasing evidence supports a correlation between
MDSCs frequency and clinical outcome, allowing to pos-
tulate MDSCs as cell biomarkers of tumor progression
and chemotherapy response in cancer patients.126 Circu-
lating MDSCs levels are elevated in cancer patients,
including lung, colon, uterus, cervix, bladder, thyroid
gland cancers, and advanced nonsmall cell lung cancer
(NSCLC) patients; the presence of these cells is inversely
correlated with clinical response.127,128 In melanoma,
lung, breast, and colorectal cancer, the abundance of
MDSCs in the tumor has been correlated with the
advanced stage and decreased overall survival.129 In
patients with early and locally advanced cervical cancer,
the frequency of circulating PMN-MDSCs is mainly cor-
related with tumor recurrence.130 Furthermore, elevated
MDSCs levels may predict cancer response to chemother-
apy and make them eligible targets for onco-
immunotherapy.131,132
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DERIVED SUPPRESSOR CELLS
Increased TME-associated TGF-β1 levels strongly corre-
late with poor prognosis and may be a prognostic or pre-
dictive biomarker in cancer patients.133 Besides cancer
cell overexpression of TGF-β1 within the TME, several
nontransformed cells also contribute to increased
intratumor TGF-β1 levels, such as cancer-associated
fibroblasts and innate-immune cells.60,134
Today, it is clear that tumor-produced TGF-β1 can
regulate MDSCs expansion and function. The main
aspects of TGF-β1 and MDSC interplay with the immune
system are summarized in Figure 2. TGF-β1, in combina-
tion with GM-CSF, induces in vitro M-MDSCs expansion
from purified human monocytes.135 Moreover, M-MDSCs
generated in the presence of TGF-β1 are more effective in
suppressing T-cell proliferation and in the induction of
Tregs.136 In a mouse breast cancer model, exosomes con-
taining TGF-β1, in collaboration with PGE2, increase
MDSCs frequency that exhibits functional characteristics
and promote tumor growth.137 MicroRNAs also contrib-
ute to MDSCs expansion by TGF-β1. TGF-β1 upregulates
miR-21 and miR-155 expression, which induces in vitro
mouse PMN-MDSCs and M-MDSCs, with strong T-cell
immunosuppression capacity.103 Besides, TGF-β1 pro-
motes MDSCs proliferation and accumulation by miR-
494 induction, in a Smad3 dependent way, in a murine
cancer model.138 Furthermore, TGF-β1 produced by B
regulatory cells (Bregs) contributes to educating both
PMN-MDSCs and M-MDSCs to suppress T-cell prolifera-
tion and cancer killing by CD8+ T lymphocytes; this lies
in part with increased MDSCs-associated iNOS and
ARG1 expression, and ROS levels.139 TGF-β1 seems to
promote MDSCs generation by an autocrine feedback
loop since TGF-β1 treated monocytes increase endoge-
nous TGFB1 gene transactivation and protein expression
that contribute to the consolidation of M-MDSCs pheno-
type and their immunosuppressive potential.136 More-
over, the TGF-β1 expression and release in MDSCs are
regulated by transmembrane TNF-α, ribosomal protein
S19-complement C5a receptor-1 interaction, and
semaphorin 4D.140-142
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TGF-β1 and MDSCs largely contribute to cancer progres-
sion. Both play crucial roles in creating an immunosup-
pressive TME by directly acting on tumor-infiltrating
immune cells, which results in cancer cells protection
from immunosurveillance and promotion of tumor
growth and malignancy.
8.1 | TGF-β1 and MDSC on T-cell
functions
TGF-β1, in general, play essential roles in the critical
steps of the T-cell antitumor response, including T-cell
activation,143 proliferation,144 differentiation,145 and
migration,146 in both the TME and tumor-draining lymph
nodes.4 It is well accepted that cytotoxic CD8+ T-cells are
among the primary effectors of anticancer immunity.147
Tumor-associated TGF-β1 inhibits the cytotoxic effects of
CD8+ T-cells by direct repression of the cytolytic gene
FIGURE 2 TGF-β1 and MDSCs cooperative regulation of the immune system. Both TGF-β1 and MDSCs exert potent immune-
suppressive functions on many cellular components of the immune system. In TME, cancer cells may express and release large TGF-β1
levels contributing to MDSCs induction and expansion. MDSCs also produce TGF-β1 that may create a regulatory loop on immune cells.
TGF-β1 inhibits T lymphocytes' activation and function (T-cells) and induces a shift toward T regulatory (Tregs) phenotype that, by secreting
TGF-β1, augments the immunosuppressive TME milieu. Moreover, MDSC/TGF-β1 axis may induce B regulatory cells (Bregs), while Bregs
may increase MDSCs frequency and function via TGF-β1 signaling. MDSCs via cell-surface-bounded TGF-β1 or soluble TGF-β1 inhibits
natural killer (NK) proliferation and cytotoxicity activity. Finally, both MDSCs and TGF-β1 participate in the enhancement of cancer cell
malignancy by promoting tumor progression. Black arrows mean induction, blue arrows mean TGF-β1 expression and release into TME,
and red dotted arrows mean inhibition
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programs, including perforin, granzyme A and B,
interferon-γ and Fas ligand expression.148,149 TGF-β1 sup-
presses tumor-specific cytotoxic T-cell proliferation
through inhibition of c-Myc expression and induction of
Smad3-Foxp1 interaction.150 Furthermore, TGF-β1
inhibits IL-2 production and its receptors, in part by
reducing nuclear factor of activated T-cells (NFAT)
nuclear translocation in effector and memory T-
cells.151,152 Moreover, SH2 domain-containing protein
tyrosine phosphatase-1 is induced under TGF-β1 treat-
ment that represses the protein tyrosine kinase activities
required for TCR signaling,153,154 Thus, T-cells within a
TME with increased TGF-β1 expression levels cannot
mount a cytolytic response against cancer cells, and this
cytokine contributes to cytotoxic T-cell exhaustion.148
MDSCs have been postulated as highly immune-
suppressive cells involved in endogenous and exogenous
inflammatory insults.84 Despite MDSCs' capacity to regu-
late almost all immune cells, T cells' inhibition is critical
and seems to be a sufficient functional criterion to define
MDSCs. MDSCs exert their suppressive effects on T cells
via several mechanisms. For instance, depletion of
metabolites required for T-cell functions implicates the
expression of ARG1 and iNOS; both consume L-arginine
(L-arg), affecting T-cell expansion due to downregulation
of CD3δ expression and inhibition of cyclin D3 and cdk4
expression.155-157 Meanwhile, iNOS catabolizes L-arg for
NO production, reducing T-cell proliferation by
inhibiting IL-2 expression.158,159 MDSCs also express
NOX2 that elevates ROS levels and contributes to per-
oxynitrite production, which induces T-cell apoptosis by
T-cell receptor (TCR) tyrosine nitration and reduction of
TCRζ chain expression.94,160 Interestingly, MDSCs can
survive hostile oxidative stress conditions by expressing
nuclear factor E2-related factor 2 (Nrf2), enhancing
MDSCs survival within TME.84,161 Besides, IDO
expressed by MDSCs also contributes to T-cell immuno-
suppression. IDO converts active metabolites such as
kynurenine. Tryptophan depletion inhibits the mechanis-
tic target of rapamycin complex 1 (mTORC1), provoking
T-cell proliferation arrest and apoptosis, while the cyto-
toxic kynurenine metabolite promotes CD4+ T-cell
exhaustion.162-164 Furthermore, MDSCs can reduce
intratumoral cysteine levels that inhibit T-cell activation
and induce apoptosis.165,166 Besides, MDSCs suppress T-
cell activation and induce apoptosis by programmed
death-1 ligand (PD-L1) binding to PD-1 expressed in T-
cells.167,168 Moreover, MDSCs also interfere with T-cell
trafficking and restrict access to TME. MDSCs, via high
mobility group box 1 (HMGB1), downregulates T-cell
expression of L-selectin, and by MMP17 cleaves cell sur-
face L-selectin, thereby limiting T-cell homing to periph-
eral lymph nodes and tumors.97,169,170
TGF-β1 produced by MDSCs from NSCLC patients, in
an autocrine way, induces MDSC CD39/CD73 expression
via the HIF-1α/mTOR axis, which enhances the capacity
of MDSCs to provoke T-cell inhibition and reduction of
NK cell surveillance activities.171 In turn, M-MDSCs from
melanoma patients can inhibit T-cell proliferation ex vivo
via paracrine TGF-β1 production, as was demonstrated
by specific neutralizing anti-TGF-β1 monoclonal anti-
bodies.14,172 Moreover, MDSCs-derived TGF-β1 increases
PD-1 expression in CD8+ T-cells, contributing to PD-1/
PD-L1 therapy resistance within TME.173
8.2 | MDSC and TGF-β1 on CD4+
regulatory T-cells
Tregs negatively regulate the effector T-cells function and
maintain the homeostasis of the immune system. Usu-
ally, in healthy organs, Tregs are present in a low num-
ber. However, Tregs increase dramatically in cancer and
contributes to tumor antigen tolerance, facilitating cancer
cells to escape immunosurveillance.2 Tregs are usually
recognized as a specialized CD4+ T-cell subset.174 TGF-β1
also regulates CD4+ T-cell function. For example, in a
mouse cancer model, the inactivation of TGF-β1 signal-
ing permits CD4+ T-cells to adopt cytotoxic T-cell-like
and NK-like phenotypes that contribute to tumor eradi-
cation. On the contrary, TGF-β1 drives the differentiation
of CD4+ T-cells toward a suppressive Tregs pheno-
type.4,175 Tregs are CD4+CD25− T-cells produced by
TGF-β1 in a Foxp3 induction in a Smad2 and
Smad3-dependent manner. This cytokine suppresses CD4
+ and CD8+ T-cell proliferation while inhibiting CD8+
T-cell formation and their interferon (IFN)γ-dependent
cytolytic activities.58,176-178 Regarding MDSCs, these cells
induce the expression and expansion of Foxp3+CD25+
Tregs in vitro, whereas adoptive cell transfer of MDSCs
induces suppressive Tregs in a mouse colon carcinoma
model.179
Furthermore, Tregs can be induced and recruited by
MDSCs-derived TGF-β1, IFNγ, and IL-10 and the interac-
tion of MDCS-expressed CD40 with CD40-ligands in
Tregs.156,180 Nonetheless, the M-MDSCs subset seems to
be mainly Tregs inductors, while PMN-MDSCs do not
induce Tregs differentiation, and they can harm the
capacity of TGF-β1 to promote Tregs differentiation.181
Interestingly, MDSCs and Tregs may be mutually
regulated by establishing a positive feedback loop -
Tregs stimulate MDSCs expansion and their immuno-
suppressive functions.182 For instance, Tregs depletion
provokes a reduction of both PD-L1 and IL-10 expres-
sion by MDSCs,183 while CD80 expression in MDSCs,
which is required for MDSCs-mediated antigen-specific
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T-cell suppression, depends on Tregs and cytotoxic T-
lymphocyte antigen (CTLA)-4.184
Moreover, Tregs regulate MDSCs expansion and dif-
ferentiation through TGF-β1 and PD-L1/B7-H1 expres-
sion.182 Moreover, the Foxp3+ Treg phenotype can be
induced by switching from Th17 T-cell phenotype
through MDSCs-derived TGF-β1 and retinoic acid.185
Hence, MDSCs and Tregs seem to cooperate to enhance
TME immunosuppression reciprocally.14
8.3 | TGF-β1 and MDSCs on natural
killer cells
NK cells, which are cytolytic and cytokine-producing
effector innate lymphoid cells, represent the first defense
line against virally infected and transformed cells.186
TGF-β1 potently regulates NK cell function and metabo-
lism.187 For instance, NK cells stimulated with IL-2 in
the presence of TGF-β1 showed reduced oxidative phos-
phorylation, glycolytic capacity, and respiratory capacity,
independently of the metabolic regulator's involvement
in mTORC1. These effects rely on the canonical TGF-β1
pathway, involving Smad2/3, paralleled with the inhibi-
tion of CD71, IFNγ, and granzyme B production.188
Other authors demonstrated that mTORC1 might be
involved in TGF-β1 effects on NK cells. Peripheral NK
cells, obtained from patients with metastatic breast can-
cer, showed reduced metabolism and mTORC1 response,
and under ex vivo TGF-β1 neutralization, they recovered
oxidative phosphorylation activity, mTORC1 response,
and IFNγ expression and release.189
Furthermore, TGF-β1 in both mouse and human NK
cells inhibits IL-15-induced activation of the kinase
mTOR. Meanwhile, a TβR2 deletion enhances mTORC1
activity and NK cell cytotoxic activity under IL-15 treat-
ment, concomitantly with cancer metastasis inhibition in
tumor mouse models. Moreover, TGF-β1 and mTOR
inhibition in vitro reduced NK cell cytotoxic activity,
while TGF-β1 signaling activation or mTOR depletion
in vivo impaired NK cell development.190 Besides, TGF-
β1 treatment of NK cells ex vivo can downregulate the
natural killer group 2 member D (NKG2D) and NKp30
receptor expression, two surface receptors that mediate
the recognition of stressed and malignant transformed
cells, which may explain the reduction of antitumor NK
cell capacity.191 Congruently, TGF-β1 is implicated in
reducing NKG2D expression in NK cells in a murine
model of HNSC.192 Meanwhile, in human HNSC patients
with high TGF-β1 circulating levels, NK cells exhibit
decreased activating receptor NKp46 and both inhibitory
and activating killer Ig-like receptor expression.148,193
Furthermore, in genetically engineered mouse cancer
models, the TGF-β1/Smads axis facilitates immune
escape by causing NK cell transdifferentiation toward
type-1 innate lymphoid cell population, which does not
exhibit cytotoxic function within TME.194,195
MDSCs can also interact with and regulate cancer
cytotoxic NK cells.196 Indeed, T cell lymphoma-bearing
mice accumulate spleen MDSCs with a high capacity to
inhibit NK cells in vitro. When these MDSCs are adop-
tively transferred into mammary adenocarcinoma-
bearing mice, they suppress NK cytotoxicity, mainly by
reducing perforin production within tumors. Moreover,
MDSCs-mediated inhibition of NK cell cytotoxicity is
cell-cell contact-dependent as it was demonstrated by
in vitro MDSC-NK cocultures. Interestingly, in these
experimental conditions, MDSCs in NK cells inhibit IL-2
activation of JAK3-STAT5 signaling, which is implicated
in the induction of perforin, IFNγ, and granzyme-B
expression.197 Conversely, Gr-1+ CD11b+ F4/80+ mye-
loid cells isolated from lymphoma-bearing mice activate
NK cells to produce IFNγ. These cells express the retinoic
acid early inducible gene-1 (RAE-1), a ligand for the
receptor NKG2D, that partially contributes to NK-cell
activation.198 Nevertheless, increasing scientific evidence
indicates that MDSCs certainly inhibit NK cell activation
and function.196 Certainly, MDSCs inhibit NK cytotoxic-
ity by producing ROS and NO, leading to the nitration of
downstream signaling effectors of FcgRIIIA, while MDSC
coculture inhibits IFNγ and TNFα secretion in NK cells.
Moreover, MDSCs-derived NO also nitrates STAT1 in NK
cells, resulting in reduced interferon responses.199,200 L-
arg depletion and Kyn production by MDSCs-associated
ARG1 inhibits NK cell surface expression of NKp46 and
NKG2D activating receptors concomitantly with reduced
cell function.201 Moreover, L-arg depletion also down-
regulates the expression of CD247, an essential subunit of
natural cytotoxicity receptors (NCRs) NKp46, NKp30,
and Fcγ RIII (CD16) in NK cells, leading to the inhibition
of T-cell and NK cell proliferation and cellular anergy.
Furthermore, MDSCs, by interacting with the NKp30
receptor, may inhibit NK cell function.202,203
MDSCs-derived TGF-β1 also contributes to the regu-
lation of tumor-associated NK cells.196 Tumor-derived
prostaglandin-E2 (PGE2) derived from melanoma
patients results in an induction of M-MDSCs that, pri-
marily through TGF-β1, suppress NK cell antitumor
activity, as demonstrated by using TGF-β1 blocking anti-
body. Moreover, PGE2 activates p38 and ERK MAPK
pathways in MDSCs to enhance the secretion of TGF-β1.
Notably, upon MDSCs coculture, the NK expression
levels of NKG2D, NKp46, and NKp44 were significantly
reduced on IL2-activated cells, while PGE2 inhibition
restores NK cell activity.204 In addition to soluble TGF-
β1, MDSCs utilize membrane-bound TGF-β1 to suppress
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NK cell function and induce anergy in a cell contact-
dependent manner in liver cancer-bearing mice.14,205
Interestingly, MDSCs obtained from NSCLC patients
express CD39 and CD73 via TGF-β1-mTOR-HIF-1 signal-
ing activity.171 CD39 converts extracellular ATP to AMP,
and CD73 converts AMP to adenosine, then elevated
adenosine levels inhibit NK cell antitumor activity due to
the blocking of granzyme exocytosis, impairing perforin
and Fas ligand-mediated cytotoxic activity and by reduc-
ing IFNγ/TNFα expression and release.206-208 Therefore,
elevated intratumor MDSCs frequency and TGF-β1 levels
provoke a dysfunctional NK cell activity, resulting in a
drastic reduction of the innate response, increasing can-
cer cells' capacity to escape from immune surveillance.
8.4 | TGF-β1 and MDSC on regulatory B
cells
Bregs cells are a B cell subtype with immunosuppressive
functions that inhibit proinflammatory lymphocytes during
pathological conditions. Consequently, Bregs suppress the
tumor immune response and promote tumor growth and
progression.8,14 For instance, MDSCs promote Bregs and sup-
press overall B cell function by IL-10 and TGF-
β1 secretion,131,209 and in a 4T1 breast cancer model, MDSCs
induce PD-L1-expressing Bregs that inhibit T-cell function
and induce T cell apoptosis.210 As mentioned above, Bregs
also educate MDSCs through TGF-β1 signaling,139 which
suggests a putative positive interaction between both types of
cancer cells. Therefore, Bregs contribute to MDSC function,
and MDSCs promote Bregs expansion in cancer patients.210
9 | PERSPECTIVES FOR THE
POTENTIAL COMBINED
TARGETING OF MYELOID-
DERIVED SUPPRESSOR CELLS AND
TGF-Β1 IN CANCER
IMMUNOTHERAPY
Due to their importance in creating an immunosuppres-
sive TME, both TGF-β1 and MDSCs are attractive targets
for cancer immunotherapy.
9.1 | Targeting TGF-β1 and MDSCs
Several strategies have been developed for anti-TGF-β1
oncotherapies. These include TGF-β1-neutralizing antibodies,
peptide inhibitors, TGF-β1 receptor kinase inhibitors, anti-
sense oligonucleotides, TGF-β1 ligand traps, bifunctional anti-
bodies/biomolecules, and bifunctional chemical inhibitors.
These developed compounds may reduce excessive TGF-β1
production and bioavailability or interfere with TGF-β1 sig-
naling pathways in cancer patients.211-217 All these therapeu-
tic policies have led to a constant increase in clinical studies,
either as monotherapies or in combination with different che-
motherapies that are nicely reviewed by Derynck et al,4
Teixeira et al,217 and Huang et al.218
MDSCs are also important targets for antitumor thera-
peutic strategies. In this sense, an increasing number of sci-
entific investigations have been performed to impede
MDSCs expansion or reduce their number and revoke
MDSCs immunosuppressive functions.131,219 Current thera-
pies targeting MDSCs may consider mainly the next strate-
gies: inhibition of immunosuppressive function220;
depletion from TME and vascular circulation221,222; abroga-
tion of MDSCs migration and recruitment into the TME;
and induction of differentiation of MDSCs into mature
myeloid cells that lack suppressive activity.131,219,223
9.2 | TGF-β1 and MDSC in immune
checkpoint
Because of the importance of TGF-β1 and MDSCs in cancer
immunosuppression, several combined strategies with
immune checkpoint inhibitors (ICI) have recently emerged
that may lead to prolonged anticancer responses
(Figure 3).217 For instance, combined strategies targeting
TGF-β1 and PD-1 have been developed in preclinical cancer
models and clinical trials (NCT02947165) to improve immu-
notherapy by reducing TGF-β1 enhancing ICI tumor resis-
tance.4,224 Moreover, anti-CTLA4-TβR2 and PD-L1-TβR2
bifunctional fusion proteins increase tumor-specific IFNγ+
effector and memory cells and increased intratumoral T cell
and NK cell activation in melanoma and triple-negative
breast cancer line resistant to immune checkpoint blockade,
and murine breast and colon cancer models.225,226 Mean-
while, immunotherapies also consider ICI's combination
with MDSCs-targeting approaches (Figure 3).131 Currently,
immunotherapies include the use of PD-1 antibodies and
CTLA-4.227 Several clinical trials that consider molecules
and biomolecules for inhibition of MDSCs suppressive func-
tion, depletion, blocked migration, and differentiation
induction combined with ICI, reviewed in Wang et al,131
may demonstrate the suitability of targeting MDSCs in com-
binatory approaches with ICI in cancer therapy.
9.3 | TGF-β1 and MDSCs in chimeric
antigen receptor T-therapy
Interestingly, adoptive transfer that considers ex vivo
expanded genetically engineered T cells with chimeric
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antigen receptor (CAR) combined with TGF-β1 inhibition
or MDSCs targeting are now under consideration for can-
cer immunotherapy (Figure 3).
Immune suppression mediated by TGF-β1 is one of
the main obstacles to the success of adoptive cell therapy
to treat solid tumors.228 For instance, CAR T cells resis-
tant to TGF-β1 repression,229 such as knocking off TβR2
in CAR T cells by CRISPR/Cas9 technology, reduced the
induced Tregs conversion and prevented CAR T-cell
exhaustion230; CAR in T-cells directed to prostate-specific
membrane antigen and TβR2 dominant-negative mutant
co-expression (CART-PSMA-TGFβRDN cells) have
shown to increase proliferation, exhaustion resistance,
and enhanced cytokine release by engineered lympho-
cytes.231 Therefore, this may establish new routes and
encourage the clinical use of engineered CAR T-cells
with anti-TGF-β function to target immunosuppressive
TME due to increased levels of TGF-β1.
Clinical data show that patients with an increased
number of myeloid cells have poorer outcomes to CAR T-
cell therapy, which points out the need to reduce the
number or abolish the immunosuppressive function of
MDSCs to improve the success of CAR T-cell antitumor
activity (Figure 3). MDSCs, due to their inherent suppres-
sion capabilities, may reduce gene transfer, activation,
killing, and cytokine production in CAR T-cells. In this
sense, T cells expressing first-generation disialoganglioside
(GD2)-specific CAR in co-administration with all-trans ret-
inoic acid to reduce MDSCs number resulted in enhanced
antitumor effects against sarcoma xenografts in vivo.232
Furthermore, in mouse models, MDSCs depletion with
anti-Gr1 Ab significantly increases in vivo antitumor effect
of CAR T-cell treatment combined with polyinosinic poly-
cytidylic acid.233 Similarly, targeting MDSCs with the anti-
CD33 immunotoxin gemtuzumab ozogamicin was shown
to enhance anti-GD2-/mesothelin-/EGFRvIII-CAR-T-cell
activity and in vitro cytotoxicity against cancer cell lines.234
Moreover, Boucher et al235,236 have engineered CAR T-
cells with null mutations of CD28 subdomains resistant to
MDSCs inhibition both in vivo and in vitro. These mutant
CD28 endodomain CAR T cells also express reduced levels
of exhaustion-related transcription factors and genes, such
as Nfatc1, Nr42a, and Pdcd1, and better survival function
than unmodified CAR T-cells.
FIGURE 3 Potential collaboration of TGF-β1 and MDSCs targeting for cancer immunotherapy. TGF-β1 and MDSCs, due to their
immunosuppressive actions on cytotoxic T-cells, reduce the therapeutic outcome of immunotherapy regimen of immune checkpoint inhibitors
(ICI) and adaptive CAR T-cell transfer strategies. Potential combined therapies involving ICI and CAR T-cell immunotherapies targeting either
TGF-β1 and MDSCs individually or by simultaneous TGF-β1/MDSCs inhibition can improve immunotherapy achievement. PD-1, programmed
death 1; PD-L1, programmed death ligand-1; CTLA-4; cytotoxic T lymphocyte-associated antigen 4; B7, costimulatory molecule; CAR T-cells,
chimeric antigen receptor T cell lymphocytes; scFv, single-chain variable fragment of tumor antigen-binding domain derived from a mAb(s)
against a tumor-associated antigen linked to costimulatory domains motifs to induce optimal T-cell activation. Red arrows mean inhibition
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Although several clinical trials addressing targeting
TGF-β1 or MDSCs cancer frequency have been established
or are currently ongoing (https://clinicaltrials.gov/), no
clinical trials targeting TGF-β1 to reduce cancer-associated
MDSCs, alone or in combination therapy has been devel-
oped yet. Nevertheless, the mutual regulation between
TGF-β1 and MDSCs, as exposed in the present review,
suggests the value of targeting TGF-β1 and MDSCs
populations as part of combined approaches in immune
oncotherapies. Moreover, recent advances in immunother-
apy combinations that include TGF-β1 targeting, MDSCs
ablation to improve immunotherapy, and CAR T-cell anti-
tumor efficacy (Figure 3) make the combined TGF-
β1-MDSCs strategy promising since it may positively
enhance the potency of immunotherapy and improve pre-
cision medicine for cancer therapy.
10 | CONCLUDING REMARKS
Extensive studies conducted over the last decades have
demonstrated that it is essential to unveil the TME-
associated immunosuppressive, cellular, and molecular
mechanisms. In this review, we attempt to address the
main clues of the diverse roles of both TGF-β1 and
MDSCs in creating and maintaining an immunosuppres-
sive cancer milieu and repression of immunosurveillance.
TGF-β1, either by directly regulating the immune
response or by inducting MDSCs and contributing to the
regulation of T-cell mediated immune functions and
mediating the induction of Tregs and Bregs, may create
immune-tolerant conditions that protect cancer cells
from immune clearance. Moreover, the MDSCs capacity
to express and release TGF-β1 may generate positive feed-
back that highly amplifies protumorigenic MDSCs activ-
ity. TGF-β1 increases recruitment, expansion, survival,
and differentiation of immunosuppressive MDSCs, and
autocrine TGF-β1 seem to be essential to maintain the
immunosuppressive MDSCs phenotype.
Besides, TGF-β1 and MDSCs, due to their critical
roles in tumorigenesis, are attractive targets for cancer
immune therapy. Currently, a growing number of clinical
trials address the combination of immunotherapy with
inhibition of TGF-β1 signaling. Meanwhile, clinical trials
also address the elimination and full maturation induc-
tion of MDSCs to improve chemotherapy and immuno-
therapies. A potential combination of anti-TGF-β1 and
anti-MDSCs strategies may impede the amplification loop
operating between TGF-β1 and MDSCs in cancer and
could limit tumor progression and metastasis by
impairing tumor dissemination and immunosurveillance
escape. Indeed, clarifying the complex interplay of TGF-
β1 and MDSCs in cancer is critical for understanding
their mutual contribution to cancer initiation, progres-
sion, immune-resistance, and metastasis and may reveal
potential combinatory clinical treatments to increase the
success of immunotherapy in the control of cancer
development.
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